Introduction {#s1}
============

Invasive aspergillosis (IA) is the most common opportunistic invasive fungal infection in immunocompromised patients, especially those with prolonged neutropenia [@pone.0028467-Walsh1]. In patients with hematological malignancies (HM), the prevalence of IA ranges from 1--15% and mortality can reach as high as 90%, despite the availability of several active antifungal agents [@pone.0028467-Walsh1].

Early diagnosis of IA remains a challenge, and few diagnostic methods are available. The galactomannan (GM) assay may be useful in establishing an earlier diagnosis and may result in improved outcomes for immunocompromised patients [@pone.0028467-Pfeiffer1], [@pone.0028467-Leeflang1]. The specificity of GM detection in serum generally reaches over 90%. In bronchoalveolar lavage fluid (BALF), GM detection can lead to an earlier diagnosis of IA in patients with HM, yielding an increased sensitivity when compared with serum, e.g., 85--100% versus 47% [@pone.0028467-Becker1].

Molecular diagnostic techniques such as nucleic acid detection by polymerase chain reaction (PCR) are emerging as potentially more sensitive and rapid than conventional techniques for the diagnosis of IA [@pone.0028467-Donnelly1], [@pone.0028467-Hope1]. In addition to being helpful in IA diagnosis, DNA amplification with an integrated system for species-level identification based on melt-curve profiles or via an additional probe, would be useful to save time and refine the diagnosis of specific infections, allowing for administration of targeted antifungal therapy based on species-level identification [@pone.0028467-Khot1]. A systematic review, which assessed the use of PCR on blood and serum samples, showed its clinical value and recommended standardization of PCR platforms [@pone.0028467-Mengoli1].

BALF is routinely used to assess for the presence of fungi at the site of pulmonary infection. Conventional microbiological techniques like culture and histology of BALF are most commonly used for the diagnosis of IA, but these techniques have suboptimal sensitivity [@pone.0028467-Reichenberger1]. Detection of *Aspergillus* DNA in BALF yields high sensitivity and specificity. One review evaluated 15 clinical studies investigating the diagnostic efficiency of performing PCR on the BALF of IA patients and showed a promising clinical significance although with some methodological limitations [@pone.0028467-Tuon1]. Using a bivariate regression approach, we have now undertaken a systematic review of all eligible, and more recent, clinical studies to assess the accuracy of BALF-PCR as a diagnostic test for IA in immunocompromised patients.

Materials and Methods {#s2}
=====================

Two investigators searched MEDLINE and EMBASE for relevant articles published up to December 2010 for Medical Headings and text words that included the search terms "aspergillosis," "*aspergillus*," "polymerase chain reaction" and "bronchoalveolar lavage". The syntax for the MEDLINE searches was as follows: "aspergillosis" OR "*aspergillus*" AND "polymerase chain reaction" AND "bronchoalveolar lavage". The reference lists of the included studies and review articles were also checked for further relevant studies. Searches were restricted to English-language literature on human subjects only; abstracts or meeting proceedings were excluded. The results were then manually searched for eligible studies. Full-text publications concerning PCR on BALF were included if (1) they used the European Organization of the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) or the revised EORTC/MSG criteria, as a reference standard [@pone.0028467-Ascioglu1], [@pone.0028467-DePauw1], (2) for studies published before the designation of these criteria in 2002, equivalent but non-identical criteria were used as a reference standard, (3) the studies reported the data separately on true-positive, false-positive, false-negative, and true-negative results of the diagnostic tests, and (4) the studies included immunocompromised or at-risk patients. To avoid selection bias, studies with populations fewer than 10 were excluded.

Data extraction was performed independently by two reviewers and any uncertainties or disagreements were resolved by discussion. The quality of the selected studies was assessed as recommended in the Standards for the Reporting of Diagnostic Accuracy (STARD) by using 14 items of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) lists [@pone.0028467-Bossuyt1], [@pone.0028467-Whiting1].

Statistical analysis {#s2a}
--------------------

To calculate test accuracy, we defined proven and probable patients as having IA, and possible and no IA patients as not having IA, to construct two-by-two tables, according to the revised EORTC/MSG criteria [@pone.0028467-DePauw1]. We also constructed other two-by-two tables (proven IA vs probable, possible, and no IA).

By undertaking a bivariate regression approach, we calculated pooled estimates of sensitivity (SEN) and specificity (SPE) as the main outcome measures, and constructed hierarchical summary receiver operating characteristic (SROC) curves [@pone.0028467-Reitsma1]. Based on random-effects models, this bivariate approach investigates potential between-study heterogeneity and incorporates the possible correlation between the SEN and the SPE. Using the pooled SEN and SPE, positive and negative likelihood ratios (PLR and NLR, respectively) were also calculated.

Heterogeneity was assessed through the test of inconsistency (*I^2^*) of the pooled diagnostic odds ratios (DORs) [@pone.0028467-Higgins1]. DOR indicated the accuracy of a diagnostic test, corresponding to particular pairings of SEN and SPE. It illustrated the odds of positive test results in participants with the disease compared with the odds of positive results in those without the disease. The mean DOR was used as an accuracy index and was performed by classic meta-analytic pooling [@pone.0028467-Deeks1].

Potential heterogeneity was explored by subgroup analyses [@pone.0028467-Lijmer1], [@pone.0028467-Petitti1]. Covariates clearly reported by more than 80% of studies were analyzed: population (only HM vs. mixed/other), design (cohort vs. case-control), data collection (prospective vs. retrospective), EORTC/MSG criteria (yes vs. no), PCR method (quantitative vs. other), primer design (*A.fumigatus*-specific vs. other), cell wall disruption method (commercial vs. "in house"), and DNA extraction method (commercial vs. "in house"). Deeks\'s funnel plot was used to inspect publication bias [@pone.0028467-Deeks2]. Posttest probability(PTP) was calculated by using the overall prevalence of 19% with Fagan nomograms [@pone.0028467-Fagan1]. All analyses were performed using STATA, version 10 (Stata Corp., College Station, TX) with the module "Midas" [@pone.0028467-Fagan1]. All statistical tests were two sided, with *P* values less than 0.05 denoting statistical significance.

Results {#s3}
=======

Our search criteria identified 2361 studies from literature. After screening the titles and abstracts, 101 articles were selected for full-text review and 84 studies were discarded for various reasons. In two publications with suspected overlapping data from the same medical services, we chose to include the larger of the studies [@pone.0028467-Buchheidt1], [@pone.0028467-Buchheidt2]. Ultimately, 17 studies with 1191 patients met the inclusion criteria and were included in the systematic review [@pone.0028467-Buchheidt2]--[@pone.0028467-Verweij1].

The characteristics of these studies are detailed in [Table 1](#pone-0028467-t001){ref-type="table"}. Overall, there were 1296 clinical BALF samples from 1191 patients. Most patients with HM received either chemotherapy or a hematopoietic stem-cell transplant. The average prevalence of proven and probable IA across cohort studies was 19% (range: 5.77--47.37%), which was higher than that reported in some studies [@pone.0028467-Leeflang1], [@pone.0028467-Pfeiffer2]. The relatively higher prevalence might result from the different populations among these reviews. The participants of the included studies mainly constituted patients with HM accompanied by pulmonary infiltration.

10.1371/journal.pone.0028467.t001

###### Characteristics of studies included in the analysis.

![](pone.0028467.t001){#pone-0028467-t001-1}

  Study                                      Study population                       Age group   Sample processing   Study design             Reference standard              Radiology-based BALF   Patients (*n*)   Proven and probable IA (*n*)
  ---------------------- --------------------------------------------------------- ----------- ------------------- -------------- ----------------------------------------- ---------------------- ---------------- ------------------------------
  Bretagne 1995^24^                               HM, HIV                              NR          Prospective         Cohort      Similar[1](#nt101){ref-type="table-fn"}            NR                  52                      3
  Buchheidt 2002^23^                        allogeneic HSCT, HM                       Adult        Prospective         Cohort                      Similar                            Y                  141                      26
  Frealle 2009^25^                                  HM                                Adult       Retrospective     Case-control                  EORTC/MSG                           NR                  57                      25
  Hayette 2001^26^                              HM, SOC, CD                            NR         Retrospective        Cohort                      Similar                            NR                  74                      10
  Jones 1998^27^                                    HM                                 NR         Retrospective     Case-control                   Similar                            NR                  69                      12
  Khot 2008^28^           HSCT, HM, pulmonary infiltrates suggestive of pneumonia     Adult       Retrospective        Cohort                     EORTC/MSG                           Y                   81                      13
  Melchers 1994^29^                                 HM                                Adult       Retrospective     Case-control                  EORTC/MSG                           NR                  14                      6
  Musher 2004^30^                                  HSCT                                NR         Retrospective     Case-control                  EORTC/MSG                           NR                  93                      46
  Raad 2002^31^           HM, SOC, pulmonary infiltrates suggestive of pneumonia      Adult        Prospective         Cohort                     EORTC/MSG                           NR                 249                      32
  Rantakokko 2003^32^                               HM                                 NR         Retrospective     Case-control                  EORTC/MSG                           NR                  66                      11
  Sanguinetti 2003^33^       HM, pulmonary infiltrates suggestive of pneumonia        Adult       Retrospective        Cohort                     EORTC/MSG                           Y                   44                      20
  Shahid 2008^34^                                   BC                                Adult       Retrospective        Cohort                     EORTC/MSG                           Y                   69                      23
  Skladny 1999^35^                                  HM                                 NR         Retrospective     Case-control                  EORTC/MSG                           Y                   65                      9
  Spiess 2003^36^            HM, pulmonary infiltrates suggestive of pneumonia         NR         Retrospective     Case-control                  EORTC/MSG                           Y                   31                      11
  Spreadbury 1993^37^                             HM,SOC                              Adult       Retrospective     Case-control                   Similar                            NR                  16                      3
  Tang 1993^38^                                   HM, BMT                             Adult       Retrospective     Case-control                   Similar                            NR                  50                      4
  Verweij 1995^39^                                  HM                                 NR         Retrospective        Cohort                      Similar                            Y                   19                      9

Studies that used criteria that were similar but not identical to the EORTC/MSG criteria.

Abbreviation: BALF, bronchoalveolar lavage fluid; BC, Bronchogenic carcinoma; BMT, bone marrow transplantation; CD, corticosteroid dependent; EORTC/MSG, European Organization of the Research and Treatment of Cancer/Mycoses Study Group; HIV, human immunodeficiency virus; HM, hematological malignancy; HSCT, hematopoietic stem-cell transplant; IA, invasive aspergillosis; NR, not reported; SOC, solid-organ cancer; Y, yes.

Ten studies used the EORTC/MSG criteria, whereas seven studies used similar criteria that were not identical to the EORTC/MSG criteria. Three studies included eligible patients exhibiting persistent fever who were unresponsive to first-line broad-spectrum antibiotic treatment [@pone.0028467-Frealle1], [@pone.0028467-Jones1], [@pone.0028467-Skladny1].

The details of the PCR techniques used are summarized in [Table 2](#pone-0028467-t002){ref-type="table"}. BALF was used in all studies (volume range: 0.1--5 ml). Six studies used quantitative PCR (qPCR) in *Aspergillus* DNA determination and the remainder used end-point PCR or semi-quantitative PCR. The quality of all studies was generally high, meeting on average 10 of the 14 QUADAS criteria ([Fig. 1](#pone-0028467-g001){ref-type="fig"}).

![Methodological quality graph of all 17 studies.\
Data are presented as a percentages bar across all included studies, according to the Quality Assessment of Diagnostic Accuracy Studies lists.](pone.0028467.g001){#pone-0028467-g001}

10.1371/journal.pone.0028467.t002

###### Technical details of the PCR methods used in the included studies.

![](pone.0028467.t002){#pone-0028467-t002-2}

  Study                   BALF sample volume(ml)   Samplecentrifugation[1](#nt103){ref-type="table-fn"}   Cell wall disruption    DNA extraction methods   PCR experimental method                    Primer design                    Appropriate controls  
  ---------------------- ------------------------ ------------------------------------------------------ ----------------------- ------------------------ -------------------------- ------------------------------------------------ ---------------------- ---------
  Bretagne 1995^24^                1.5                                      NR                               SDS, proteinase        Phenol-chloroform          Competitive PCR                    *A. fumigatus species*                       Yes              No
  Buchheidt 2002^23^               1.5                                     Yes                                  Lyticase            Phenol-chloroform             Nested PCR                      *Aspergillus species*                        Yes              Neg
  Frealle 2009^25^                 0.2                                     Yes                             QIAamp DNA Mini Kit            QIAamp                     qPCR                         *A. fumigatus species*                       Yes            Pos/Neg
  Hayette 2001^26^                 0.5                                      No                               SDS, proteinase        Phenol-chloroform             Nested PCR               *A. fumigatus and A. flavus species*                Yes              No
  Jones 1998^27^                   0.2                                      No                               SDS, proteinase           Gentra pure                PCR-ELISA                       *Aspergillus species*                        Yes              Neg
  Khot 2008^28^                    2--5                                    Yes                            MasterPure Yeast Kit          MasterPure                 qPCR^3^                        *Aspergillus species*                        Yes            Pos/Neg
  Melchers 1994^29^                 NR                                     Yes                               SDS, proteinase        Phenol-chloroform           End-point PCR                     *Aspergillus species*                         No              Neg
  Musher 2004^30^                  1.5                                     Yes                            MasterPure Yeast kit          MasterPure                   qPCR                         *Aspergillus species*                        Yes              Neg
  Raad 2002^31^                     1                                      Yes                               SDS, proteinase        Phenol-chloroform           End-point PCR                     *Aspergillus species*                        Yes              No
  Rantakokko 2003^32^              1.5                                     Yes                               SDS, proteinase        Phenol-chloroform                qPCR                         *A. fumigatus species*                       Yes              No
  Sanguinetti 2003^33^             1.5                                      NR                            DNeasy Plant Mini Kit           DNeasy                   qPCR^3^                        *Aspergillus species*                         No              No
  Shahid 2008^34^                  0.1                                      No                               SDS, proteinase        Phenol-chloroform           End-point PCR         *A. fumigatus, A. flavus and A. niger species*            No              Neg
  Skladny 1999^35^                  NR                                     Yes                               SDS, proteinase        Phenol-chloroform        Nested PCR(two step)                 *Aspergillus species*                        Yes              No
  Spiess 2003^36^                   NR                                     Yes                               SDS, proteinase        Phenol-chloroform      qPCR and nested PCR^3,4^               *A. fumigatus species*                        No              Neg
  Spreadbury 1993^37^              0.25                                     No                               SDS, proteinase        Phenol-chloroform           End-point PCR                     *A. fumigatus species*                       Yes              Neg
  Tang 1993^38^                    0.25                                     No                               SDS, proteinase        Phenol-chloroform           End-point PCR              *A. fumigatus and A. flavus species*                 No              Neg
  Verweij 1995^39^                  NR                                     Yes                               SDS, proteinase        Phenol-chloroform           End-point PCR                     *A. fumigatus species*                        No              Neg

Studies that used a BALF pellet for detection after centrifugation. ^2^Positive or negative extraction control. ^3^Studies that quantified the fungal load in the BALF. ^4^Study that used two PCR methods in the same population. Only the qPCR data are included.

Abbreviations: BALF, bronchoalveolar lavage fluid; ELISA, enzyme-linked immunosorbent assay; IAC, internal amplification control; Neg, negative; NR, not reported; PCR, polymerase chain reaction; Pos, positive; qPCR, quantitative real-time PCR; SDS, sodium dodecyl sulphate buffer.

Data synthesis and metaanalysis {#s3a}
-------------------------------

For all the studies, the pooled DOR was 122 (95% confidence interval (CI) 41--363). [Table 3](#pone-0028467-t003){ref-type="table"} shows the SEN, SPE, PLR, NLR, and DOR. The wide range of SEN was mainly because of the variance of IA cases in different studies. We found substantial heterogeneity among studies for all modalities because all I^2^ values were above 50%.

10.1371/journal.pone.0028467.t003

###### Synthesized statistics with two definition criteria.

![](pone.0028467.t003){#pone-0028467-t003-3}

  Patient definition                               Studies(*n*)                        DOR                           Pooled SEN          Pooled SPE             PLR                 NLR
  ----------------------------------------------- -------------- ----------------------------------------------- ------------------- ------------------- ------------------ -------------------
  Proven and probable versus possible and no IA         17        122 (41--363)[1](#nt105){ref-type="table-fn"}   0.91 (0.79--0.96)   0.92 (0.87--0.96)   11.9 (6.8--20.8)   0.10 (0.04--0.24)
  Proven versus probable, possible and no IA            8                         49 (17--140)                    0.90 (0.77--0.96)   0.84 (0.81--0.87)    5.7 (4.6--7.0)    0.12 (0.05--0.29)

Values in parentheses are 95% confidence intervals.

Abbreviations: DOR, diagnostic odds ratio; IA, invasive aspergillosis; NLR, negative likelihood ratio; PLR, positive likelihood ratio; SEN, sensitivity; SPE, specificity.

The SROC curve represents the relationship between SEN and SPE across studies, determining the presence of a threshold effect. Based on the bivariate approach which estimates not only the strength but also the shape of the correlation between SEN and SPE, a 95% confidence ellipse and a 95% prediction ellipse were drawn([Fig. 2](#pone-0028467-g002){ref-type="fig"}). The area under the SROC curve (AUC) was 0.97 (95% CI 0.95--0.98), signifying the high discriminatory ability of BALF--PCR.

![SROC curves from the bivariate model for proven and probable cases.\
The region enclosed by the dashed line (confidence contour) contains likely combinations of the mean value of sensitivity and specificity. The region enclosed by the dotted line (prediction contour) demonstrates more uncertainty as to where the likely values of sensitivity and specificity might occur for individual studies. SROC, summary receiver operating characteristic.](pone.0028467.g002){#pone-0028467-g002}

Subgroup analyses showed that the SEN of qPCR was significantly lower than that of other types of PCR ([Fig. 3](#pone-0028467-g003){ref-type="fig"}). Studies using commercial kits for cell wall disruption and DNA extraction achieved significantly higher SPE than those using an "in house" method. These covariates did not affect the SEN yet. We also found that using *A.fumigatus* species-specific primers led to a significantly lower SPE than did using other primers (mostly genus-specific primers).

![Forest plot of subgroup analyses for sensitivity and specificity.\
EORTC/MSG, similar to the European Organization of the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria 2008; Higher prevalence, prevalence above 23%; HM, hematologic malignancy; Primer AF, *A.fumigatus*-specific primer; Commercial CWD, commercial kit for cell wall disruption; Commercial EX, commercial kit for DNA extraction; \* *P*\<0.05; \*\* *P*\<0.01; \*\*\* *P*\<0.001.](pone.0028467.g003){#pone-0028467-g003}

Non-publication bias was detected by the Deek\'s funnel plot asymmetry test (*P* = 0.55) [@pone.0028467-Petitti1]. The nomogram of Fagan demonstrated that the PCR assay increased the probability of IA nearly five-fold when the results were positive, and decreased the probability to 1.5% when the results were negative ([Fig. 4](#pone-0028467-g004){ref-type="fig"})[@pone.0028467-Fagan1].

![Fagan\'s nomogram for calculating posttest probabilities (PTPs).\
A straight edge was used to link the pretest probability of IA with the PTP, by crossing the likelihood ratio line at a point that describes the results obtained. The solid line extends from the prevalence to the PLR; the dotted line extends from the prevalence to the NLR.](pone.0028467.g004){#pone-0028467-g004}

Discussion {#s4}
==========

The frequency of IA has increased with the increasing number of high-risk patients. The most common site of infection is pulmonary and IA can easily disseminate to other organs [@pone.0028467-Rapp1]. Clinically, the gold standard for the diagnosis of IA still requires an invasive procedure to provide histopathologic or cytopathologic evidence. Unfortunately, the patient\'s status often prohibits the use of invasive techniques. Culturing of the causative agent can result in false negative or false positive results. Bronchoscopy with BALF seems to be a feasible diagnostic tool, with a high yield and low complication rates [@pone.0028467-Hummel1]--[@pone.0028467-Hohenthal1].

Serum GM detection and PCR assays seem to have diagnostic potential. Clinical trials have shown that GM assays on serum or BALF and PCR assays on serum have variable performance in different at-risk patient populations. The metaanalyses of Pfeiffer st al. and Leeflang et al. both drew similar conclusion that serum GM detection was moderately useful for diagnosing IA although there were some methodological limitations in these studies [@pone.0028467-Leeflang1], [@pone.0028467-Pfeiffer2]. In Leeflang et al.\'s study, in which only proven and probable cases were considered, the overall SEN increased by 17% (from 62% to 79%) with a decrease in the threshold from 1.5 to 0.5, and the overall SPE decreased by 13% (from 95% to 82%). Mengoli et al. determined the SEN and SPE of PCR for two consecutive positive samples to be 0.75 and 0.87, respectively, and concluded that two positive tests are required to confirm the diagnosis, whereas a single PCR-negative result is sufficient to exclude a diagnosis of IA [@pone.0028467-Mengoli1]. Wang et al.\'s found that, as a diagnostic tool, the BALF-GM assay was better than serum GM detection [@pone.0028467-Guo1]. This study showed that the BALF-GM assay had a SEN of 0.90 and a SPE of 0.94 for proven and probable IA, which were both higher than the corresponding values for the serum GM assay.

We undertook the present metaanalysis aiming to establish the overall accuracy of the BALF-PCR assay for the diagnosis of IA and to help standardize PCR assay and normalize clinical performance. Our primary finding was that the BALF-PCR assay is a powerful tool for the diagnosis of IA in patients with hematological malignancy, and that the use of particular procedures can improve diagnostic accuracy. However, the increased SEN and SPE could be related to the high sensitivity of PCR, and possible existing fungal colonization in the bronchial tree of high-risk cases might contribute to the elevated SEN. Comparing the diagnostic tools examined in all former metaanalyses, the BALF-PCR assay had the highest area under the SROC curve (0.97) which meant that this assay had the best discriminative ability.

We also investigated likelihood ratios, which take into account the interaction between the SEN and the SPE in their calculation and describe the discriminatory properties of positive and negative test results. PLR \>10 and NLR \<0.1 are usually considered convincing evidence to rule in or rule out diagnoses, respectively [@pone.0028467-Jaeschke1]. Although three metaanalyses did not report these results [@pone.0028467-Leeflang1], [@pone.0028467-Mengoli1], [@pone.0028467-Pfeiffer2], the conclusions of these studies suggested that serum GM and serum PCR could not effectively discriminate IA. In our metaanalysis, for proven and probable cases, the PLR and NLR both exceeded the threshold index and generated large and often conclusive shifts from pre-test to PTP.

It is an important objective of a metaanalysis to explore the likely causes of heterogeneity [@pone.0028467-Lijmer1], [@pone.0028467-Petitti1]. In our subgroup analyses, we identified several characteristics that might account for the observed heterogeneity. The significantly lower SEN of qPCR might be due to the use of a modified PCR assay for improvement of SEN, such as nested PCR. Nested PCR formats have been widely used for *Aspergillus* in an attempt to optimize analytical sensitivity, but the requirement to open the reaction tubes means that there is considerable risk of contamination and the subsequent generation of false-positive results [@pone.0028467-Hope2]. Recently, the real-time quantitative format has become dominant in PCR-based diagnostic studies of fungal infections [@pone.0028467-Khot1]. The limit of its sensitivity was found to be five copies of *Aspergillus* DNA per milliliter; this is comparable to that of the commonly used nested PCR assay [@pone.0028467-Bolehovska1]. In addition, quantification of the fungal burden by real-time PCR may be helpful to distinguish between colonization and infection, and could possibly allow therapeutic monitoring [@pone.0028467-RantakokkoJalava1]. Nowadays, real-time qPCR is the best PCR format for clinical diagnostic application.

There is a multitude of fungal DNA extraction techniques. The selected extraction method represents a compromise between efficiency, freedom from exogenous contamination, and applicability to routine high-throughput testing. The efficiency of extraction of fungal DNA may vary considerably among commercial kits [@pone.0028467-Loeffler1], And this can hinder comparisons among studies. We found that studies that used commercial kits for cell wall disruption and DNA extraction achieved significantly higher SPE than those that used "in-house" methods. The uniform commercial kit for the GM assay contributes to its stable operation and comprehensive use, and we believe that a uniform PCR assay system may also promote the application of qPCR.

When designing primers for clinical diagnostic purposes, the detection of a broad range of fungi is important, as is the ability to increase SEN and ultimately identify the specific pathogen [@pone.0028467-Imhof1]. In our study, we found that using *A.fumigatus* species-specific primers led to a significantly lower SPE.of the use of narrow-spectrum primers that does not lead to a lower SPE could be caused by poor primer design. Some primers, which were designed based on sequencing data that was not comprehensively validated, have shown complementarity to the genomes of several other microorganisms, such as *Candida glabrata* and *Aspergillus oryzae* [@pone.0028467-Bretagne1], [@pone.0028467-RantakokkoJalava1]. During primer design, it is necessary to conduct a thorough in silico analysis based on multiple alignment of validated sequences from various databases of as many *Aspergillus* sequences as possible, plus human sequences and those of closely related fungal pathogens such as *Penicillium* and *Candida*. Since several species of *Aspergillus* are human pathogens, *A.fumigatus* species-specific primers may lower the accuracy of PCR assays. We recommend choosing *Aspergillus* genus-specific primers, to improve PCR assay accuracy. The optimal approach, in this regard, involves the application of genus-specific primers with post-amplification analysis for species determination. Genus-specific primers are directed toward conserved regions, usually within multicopy genes, which flank sequences containing species specific polymorphisms that can be exploited in post-amplification analysis [@pone.0028467-Hope2]. However, *Aspergillus* genus-specific primers might lead to a new problem. *Penicillium*, a genus phylogenetically close to *Aspergillus*, has a high likelihood of cross reactivity within a PCR assay, which might increase the false positive rate [@pone.0028467-Hope1]. All primers should be validated by a thorough in silico analysis using multiple databases.

Another potential problem with PCR is sample contamination from airborne particles. Fungal spores are ubiquitous in the environment, and may cause false positive results in PCR. Accordingly, measures to reduce exogenous fungal contamination are critical [@pone.0028467-Khot1]. A laminar flow hood in an independent laboratory should be used exclusively for DNA extraction and pre-PCR processing. Other measures to reduce contamination are a unidirectional workflow pattern (pre- to post-PCR), physically separating the laboratories for pre- and post-PCR analysis, and using aerosol-resistant pipette tips and laminar flow hoods. In addition, using the uracil-DNA glycosylase enzyme and dUTP instead of dTTP in the PCR master mix can eliminate this problem by destroying amplicons prior to PCR [@pone.0028467-Khot1]. Moreover, controls can be used to rigorously monitor contamination. Negative control reactions, comprising all the PCR reagents except the template DNA, are essential, and can be introduced at any point in theassay, such as at sample acquisition, handling, storage, and DNA extraction.

It is still difficult for BALF-PCR to distinguish colonization from invasive infection. More importantly, the isolation of *Aspergillus* from the respiratory tract should arouse vigilance, especially in high-risk patients. The isolation of *Aspergillus* from the respiratory tract may represent one of three scenarios: (1) evidence of current disease, (2) true colonization, or (3) a marker for the probable development of invasive disease. A previous study demonstrated that a positive PCR result from BALF at the time of bone marrow transplant conditioning was predictive of the subsequent development of invasive pulmonary aspergillosis [@pone.0028467-Einsele1].

The PCR assay, especially qPCR, is becoming popular in the clinical diagnosis "toolbox", such as for *Pneumocystis* pneumonia diagnosis [@pone.0028467-Huggett1]. As the operation of PCR becomes more automated, and extraction methods and targets become commercially available, this tool should play an ever-greater role. However, because at present most laboratories perform in-house PCR assays, extensive validation and standardization is requied. An initiative is currently in progress, to devise a standard for *Aspergillus* PCR screening [@pone.0028467-Mengoli1]. Once this has been achieved, formal validation shoule be possible. As long as these standardized assays are unavailable, a combination of various methods is still needed to improve the accuracy of IA diagnosis of IA.

Our study had some limitations. First, we acknowledge that the overall number of patients included in our review was relatively small. Although we aimed to incorporate all available relevact data, it is hard to ensure that no data were missed, especially unpublished data. Second, we might have introduced bias by exclusing non-English-language studies and studies with population fewer than 10. To test the latter, we reanalyzed the data including these small studies and obtained similar overall results. Third, we used the revised EORTC/MSG criteria as a reference standard which is widely accepted but not the "gold standard" for diagnosis of every patient, especially for probable IA. The disease group could be expanded when defining probable IA.
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